Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and WBRT in NSCLC brain metastases
NCT01657799Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of veliparib in non-small cell lung cancer (NSCLC) and brain metastasis (BM) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Overall Survival at 36 months. Started Oct 2012; status: completed.
02
Drugs
veliparib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastasis (BM)
Beyond the preview
Go deeper on NCT01657799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01657799.